Table of Contents
Chemotherapy Research and Practice
Volume 2013, Article ID 379870, 7 pages
http://dx.doi.org/10.1155/2013/379870
Research Article

Neurological Adverse Effects in Patients of Advanced Colorectal Carcinoma Treated with Different Schedules of FOLFOX

1Department of Pharmacology, University of Karachi, Karachi 75270, Pakistan
2Department of Pharmacy, Jinnah University for Women, Karachi 74600, Pakistan
3Ziauddin College of Pharmacy, Ziauddin University, 4/B, Block 6, Shahrah-e-Ghalib, Clifton, Karachi 75600, Pakistan
4Karachi Institute of Radiotherapy and Nuclear Medicine (KIRAN), Karachi 75330, Pakistan

Received 22 May 2013; Revised 25 August 2013; Accepted 26 August 2013

Academic Editor: Vassilios A. Georgoulias

Copyright © 2013 Nusrat Bano et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. Raymond, R. Lawrence, E. Izbicka, S. Faivre, and D. D. Von Hoff, “Activity of oxaliplatin against human tumor colony-forming units,” Clinical Cancer Research, vol. 4, no. 4, pp. 1021–1029, 1998. View at Google Scholar · View at Scopus
  2. T. André, C. Boni, L. Mounedji-Boudiaf et al., “Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer,” The New England Journal of Medicine, vol. 350, no. 23, pp. 2343–2351, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. D. Simpson, C. Dunn, M. Curran, and K. L. Goa, “Oxaliplatin: a review of its use in combination therapy for advanced metastatic colorectal cancer,” Drugs, vol. 63, no. 19, pp. 2127–2156, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. M. W. Saif and J. Reardon, “Management of oxaliplatin-induced peripheral neuropathy,” Therapeutic and Clinical Risk Management, vol. 1, no. 4, pp. 249–258, 2005. View at Google Scholar
  5. E. S. McDonald, K. R. Randon, A. Knight, and A. J. Windebank, “Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: a potential mechanism for neurotoxicity,” Neurobiology of Disease, vol. 18, no. 2, pp. 305–313, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. A. A. Argyriou, P. Polychronopoulos, G. Iconomou et al., “Incidence and characteristics of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancer,” Acta Oncologica, vol. 46, no. 8, pp. 1131–1137, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. G. Cavaletti, G. Tredici, M. G. Petruccioli et al., “Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat,” European Journal of Cancer, vol. 37, no. 18, pp. 2457–2463, 2001. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Binder, M. Stengel, R. Maag et al., “Pain in oxaliplatin-induced neuropathy—sensitisation in the peripheral and central nociceptive system,” European Journal of Cancer, vol. 43, no. 18, pp. 2658–2663, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. S. B. Park, C. S.-Y. Lin, A. V. Krishnan, D. Goldstein, M. L. Friedlander, and M. C. Kiernan, “Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy,” Brain, vol. 132, no. 10, pp. 2712–2723, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. M. C. Kiernan, S. B. Park, D. Goldstein, C. S.-Y. Lin, A. V. Krishnan, and M. L. Friedlander, “Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity,” Journal of Clinical Oncology, vol. 27, no. 8, pp. 1243–1249, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. C. L. Renn, V. A. Carozzi, P. Rhee, D. Gallop, S. G. Dorsey, and G. Cavaletti, “Multimodal assessment of painful peripheral neuropathy induced by chronic oxaliplatin-based chemotherapy in mice,” Molecular Pain, vol. 7, article 29, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. S. M. F. Jamieson, J. Subramaniam, J. J. Liu et al., “Oxaliplatin-induced loss of phosphorylated heavy neurofilament subunit neuronal immunoreactivity in rat DRG tissue,” Molecular Pain, vol. 5, article 66, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. T. Lecomte, B. Landi, P. Beaune, P. Laurent-Puig, and M.-A. Loriot, “Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy,” Clinical Cancer Research, vol. 12, no. 10, pp. 3050–3056, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. L. Gamelin, O. Capitain, A. Morel et al., “Predictive factors of oxaliplatin neurotoxicity: the involvement of the oxalate outcome pathway,” Clinical Cancer Research, vol. 13, no. 21, pp. 6359–6368, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. M. C. Kiernan and A. V. Krishnan, “The pathophysiology of oxaliplatin-induced neurotoxicity,” Current Medicinal Chemistry, vol. 13, no. 24, pp. 2901–2907, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. F. Wen, Y. Zhou, W. Wang et al., “Ca/Mg infusions for the prevention of oxaliplatin-related neurotoxicity in patients with colorectal cancer: a meta-analysis,” Annals of Oncology, vol. 24, no. 1, pp. 171–178, 2013. View at Google Scholar
  17. X. T. Xu, Z. H. Dai, Q. Xu et al., “Safety and efficacy of calcium and magnesium infusions in the chemoprevention of oxaliplatin-induced sensory neuropathy in gastrointestinal cancers,” Journal of Digestive Diseases, vol. 14, no. 6, pp. 288–298, 2013. View at Google Scholar
  18. A. Grothey, Q. Rui, D. Shaker et al., “o-0032 phase III randomized, placebo (pl)-controlled, double-blind study of intravenous calcium/magnesium (camg) to prevent oxaliplatin-induced sensory neurotoxicity (snt), n08cb: an alliance for clinical trials in oncology study1,” Annals of Oncology, vol. 24, supplement 4, Article ID iv24, 2013. View at Google Scholar
  19. Gobran and S. Nagy, “Role of calcium and magnesium infusion in prevention of oxaliplatin neurotoxicity. A phase III trial,” The Chinese-German Journal of Clinical Oncology, vol. 12, no. 5, pp. 232–236, 2013. View at Google Scholar
  20. de Afonseca, O. Samuel, M. C. Felipe et al., “Vitamin E for prevention of oxaliplatin-induced peripheral neuropathy: a pilot randomized clinical trial,” Sao Paulo Medical Journal, vol. 131, no. 1, pp. 35–38, 2013. View at Google Scholar
  21. A. Grothey, D. A. Nikcevich, J. A. Sloan et al., “Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7,” Journal of Clinical Oncology, vol. 29, no. 4, pp. 421–427, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. N. Knijn, J. Tol, M. Koopman et al., “The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients,” European Journal of Cancer, vol. 47, no. 3, pp. 369–374, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. L. A. Kottschade, J. A. Sloan, M. A. Mazurczak et al., “The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial,” Supportive Care in Cancer, vol. 19, no. 11, pp. 1769–1777, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. K. Ishibashi, N. Okada, T. Miyazaki, M. Sano, and H. Ishida, “Effect of calcium and magnesium on neurotoxicity and blood platinum concentrations in patients receiving mFOLFOX6 therapy: a prospective randomized study,” International Journal of Clinical Oncology, vol. 15, no. 1, pp. 82–87, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. W.-Y. Chay, S.-H. Tan, Y.-L. Lo et al., “Use of calcium and magnesium infusions in prevention of oxaliplatin induced sensory neuropathy,” Asia-Pacific Journal of Clinical Oncology, vol. 6, no. 4, pp. 270–277, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. L. Gamelin, M. Boisdron-Celle, R. Delva et al., “Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer,” Clinical Cancer Research, vol. 10, no. 12, pp. 4055–4061, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Wolf, D. Barton, L. Kottschade, A. Grothey, and C. Loprinzi, “Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies,” European Journal of Cancer, vol. 44, no. 11, pp. 1507–1515, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. A. J. Windebank and W. Grisold, “Chemotherapy-induced neuropathy,” Journal of the Peripheral Nervous System, vol. 13, no. 1, pp. 27–46, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. J. Graham, M. Muhsin, and P. Kirkpatrick, “Oxaliplatin. Market analysis,” Nature Reviews Drug Discovery, vol. 3, no. 1, pp. 11–12, 2004. View at Google Scholar · View at Scopus
  30. P. C. Kurniali, L. G. Luo, and A. B. Weitberg, “Role of calcium/ magnesium infusion in oxaliplatin-based chemotherapy for colorectal cancer patients,” Oncology, vol. 24, no. 3, pp. 289–292, 2010. View at Google Scholar · View at Scopus
  31. D. R. Pachman, D. L. Barton, J. C. Watson, and C. L. Loprinzi, “Chemotherapy-induced peripheral neuropathy: prevention and treatment,” Clinical Pharmacology and Therapeutics, vol. 90, no. 3, pp. 377–387, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. B. Vincenzi, M. F. Anna, S. Gaia et al., “Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV,” Supportive Care in Cancer, vol. 21, no. 5, pp. 1313–1319, 2013. View at Publisher · View at Google Scholar
  33. J. M. Schloss, C. Maree, A. Caroline et al., “Nutraceuticals and chemotherapy induced peripheral neuropathy (CIPN): a systematic review,” Clinical Nutrition, 2013. View at Publisher · View at Google Scholar